PTAB Won't Review Amgen Patent On Chemotherapy Drugs
Amgen has escaped an attempt to torpedo a patent that covers its chemotherapy-easing drugs Neupogen and Neulasta after the Patent Trial and Appeal Board found Lupin's challenge failed to prove any...To view the full article, register now.
Already a subscriber? Click here to view full article